The Lancet Oncology Response to Reviewers: How to Answer the Statistical Reviewer and Win (2026)
How to write a point-by-point response to reviewers for The Lancet Oncology, where a separate statistical reviewer runs in parallel with clinical referees and the revision bar is re-analysis, not rewording.
Readiness scan
Before you submit to The Lancet Oncology, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
The Lancet Oncology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 35.9 puts The Lancet Oncology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~8% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: The Lancet Oncology takes ~14 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Quick answer: A Lancet Oncology response to reviewers must satisfy two reviewer tracks at once, because a research paper is usually read by about three clinical reviewers plus one separate statistical reviewer, with clinical and statistical review running in parallel.
Open with a short letter to the editor summarizing the main concerns and changes, answer each comment under Reviewer 1, 2, 3 and the statistical reviewer, give the page and line number you cite for every change, and treat a statistical-reviewer concern as a request for re-analysis, not rewording. The editorial bar is practice-changing clinical impact with careful interpretation, so never overstate what the revised data support.
Start with the Lancet Oncology submission readiness check before you upload your revision, or work through this guide by hand. For broader cluster context, see the Lancet Oncology journal overview.
What does a Lancet Oncology response to reviewers require?
The Manusights Lancet Oncology rebuttal scan. This guide tells you what the handling editor, the clinical referees, and the separate statistical reviewer look for in a Lancet Oncology rebuttal. The scan tells you whether YOUR response letter clears that bar, including the statistical-reviewer block, before you submit the revision. We have reviewed clinical-oncology manuscripts and rebuttals targeting Lancet Oncology and peer Lancet-family and oncology venues; the patterns below are the same ones referees flag at re-review. Your oncology manuscript is never used to train any AI model and is deleted within 24 hours.
Three things make a Lancet Oncology rebuttal different from a generic one. Each maps to a structural feature of how the journal reviews oncology work, and each changes what your reply has to contain.
- It answers two parallel review tracks. Roughly three clinical or subject experts read your paper alongside one statistical reviewer, whose report you must answer on its own terms, with re-run numbers rather than reassurance.
- The editorial bar is practice impact with careful interpretation. The editors are asking whether an oncologist would change a tumor-board decision after reading the revised paper, and whether your interpretation stays inside what the data support.
- The revision clock is short. The Lancet group prizes speed, so the new analysis you owe the statistical reviewer often has to be planned before the decision letter even lands.
One practical constraint frames the whole revision: Lancet Oncology research Articles run to about 4,500 words of main text, which is the budget your revised manuscript still has to fit after the new analysis. Submissions and revisions are handled through the journal's online system at Editorial Manager submission portal.
Methodology note. For this Lancet Oncology guide we read the Lancet group's peer-review and author documentation, then we checked it against the Lancet's own published statistical-review audit and SciRev community reports, and we evaluated it alongside our own pre-submission reviews of oncology rebuttals. Every claim below traces to a primary source or our review corpus.
Element | What Lancet Oncology expects | What reviewers flag at re-review |
|---|---|---|
Reviewer tracks | Answer ~3 clinical reviewers AND the statistical reviewer | Treating the statistical report as one more clinical comment |
Statistical concerns | Re-run the analysis, show the new numbers | "The original analysis is appropriate" with no re-analysis |
Structure | Editor letter, then point-by-point under each reviewer | Free-form prose answering all comments together |
Specificity | Page and line number plus updated checklist item | "We have revised the manuscript" with no location |
Interpretation | Conclusions bounded to what the data support | Overstated practice-changing claims the trial cannot carry |
Reporting standards | Updated CONSORT, PRISMA, or STROBE checklist resubmitted | Checklist left unchanged after the text was revised |
Source: Lancet and Lancet Oncology peer-review and author documentation, accessed June 2026.
The copyable Lancet Oncology rebuttal template
The editors and the statistical reviewer read your rebuttal against each report in turn, so a clean, scannable structure is doing real work. Copy this skeleton, then replace the bracketed text with your own changes. Keep the reviewer text and your reply in two distinct fonts or colors, and give the statistical reviewer its own block.
Dear Editor,
Thank you for the opportunity to revise our manuscript the manuscript title
(THELANCETONCOLOGY-[ID]). We summarize below the main concerns and
the changes made in response, then give a full point-by-point reply.
The principal change is a re-analysis requested by the statistical
reviewer: we have [recomputed the primary endpoint with the corrected
model / added the multiplicity adjustment / re-run the missing-data
sensitivity analysis], and updated the CONSORT checklist accordingly.
Reviewer comments are in bold and our replies in plain text, with
revised-manuscript page and line numbers for every change.
----------------------------------------------------------------
Statistical reviewer
Comment S.1: "The primary analysis does not adjust for multiple
comparisons across the three co-primary endpoints."
Response: We agree. We have applied a [Hochberg / hierarchical]
adjustment; the primary endpoint remains significant (HR [value],
95% CI [range], adjusted p = [value]). See Methods page 11, lines
4 to 16, revised Table 2, and updated Statistical Analysis Plan in
the appendix.
Comment S.2: "Missing-data handling is not described."
Response: We have added a complete-case versus multiple-imputation
sensitivity analysis; the conclusion is unchanged. See page 13,
lines 1 to 9, and Supplementary Table 4.
----------------------------------------------------------------
Reviewer 1 (clinical)
Comment 1.1: "The practice-changing claim exceeds what a single
trial in one setting can support."
Response: We agree. We have tempered the interpretation to state
the finding informs, rather than redefines, the standard of care,
and added the external-validity caveat. Revised text appears on
page 18, lines 6 to 14.
----------------------------------------------------------------
Reviewer 2 (clinical)
Comment 2.1: "Generalizability to lower-resource settings is not
addressed."
Response: We have added a paragraph on applicability across health
systems, including LMIC implementation constraints. See page 19,
lines 2 to 12.
----------------------------------------------------------------
Reviewer 3 (clinical)
Comment 3.1: "The data sharing statement does not specify access
criteria."
Response: We have updated the Data Sharing statement to name the
repository, the access mechanism, and the availability window per
ICMJE. See page 22, lines 1 to 6.
We believe the revised manuscript now addresses each reviewer and
the statistical reviewer, and we look forward to your decision.
Sincerely,
[Corresponding author, on behalf of all authors]A Lancet Oncology reviewer scans this document for four tokens before reading a word of argument:
- an opening letter to the editor that summarizes the main concerns and the changes you made;
- a structure that breaks out each clinical reviewer and the statistical reviewer separately;
- explicit action language ("we have recomputed", "we have added", "we have updated"), never "we considered";
- a page and line reference anchoring every change in the revised file.
What sets the Lancet Oncology skeleton apart from a generic rebuttal is the dedicated statistical-reviewer block sitting at the top, where each answer is a re-run number, not a sentence.
The page-and-line rule: cite the location of every change
State the exact page and line number for every manuscript revision, and name the specific table, figure, supplementary file, or checklist item you touched. Across the Lancet family this is the single most-cited rebuttal failure.
The reason is about reader effort, not bureaucracy. A reviewer who has to hunt for your change reads it as evasion. A reviewer who can click straight to page 11, lines 4 to 16, and see the corrected survival model finishes faster and re-reviews more favorably. Never write "we have addressed this in the manuscript" without a location, and use the line numbers from the revised file, not the original.
The Lancet Oncology twist is the reporting checklist. When you change a Methods detail, cite the updated CONSORT or PRISMA item number alongside the page and line, because the editors check the resubmitted checklist against the revised text line by line. A page reference that points only at the manuscript body, with no matching checklist item, leaves half the change unverifiable.
Reviewer-text vs author-response typography
Keep the reviewer's words and your reply visually distinct. Put each comment in bold or a colored text box, with your response in plain text directly beneath it.
At Lancet Oncology this layout earns its keep because four different readers parse the same document. The handling editor, the three clinical referees, and the statistical reviewer each scan the letter looking only for their own points. When comment and reply blur together, the one reviewer whose concern is load-bearing loses the attention you need.
The Lancet-specific move is to give the statistical reviewer its own clearly labeled block at the top, so the editors can see at a glance that the re-analysis was done before they reach the clinical replies.
Tone calibration: how to phrase the hard replies
The clinical referees and the statistical reviewer all see your tone, and the editors meet to weigh the reports together. A defensive reply to the statistical reviewer is the fastest way to a rejection at Lancet Oncology, because a contested statistical concern reopens the question of whether the conclusions are justified at all. Calibrate.
Bad (defensive or vague) | Better (substantive and gracious) |
|---|---|
"The statistical reviewer has misunderstood our analysis." | "We did not describe the analysis clearly; we have rewritten the Statistical Analysis section on page 11 and re-run the model, which gives an adjusted p = [value]." |
"Adjusting for multiplicity is unnecessary here." | "We agree multiplicity should be addressed. We have applied a hierarchical testing procedure (Methods, page 11); the primary endpoint remains significant." |
"This subgroup analysis is outside the scope of our trial." | "We agree this would strengthen interpretation. We have added a pre-specified subgroup sensitivity analysis on page 14 and flagged the post-hoc exploratory subgroups as hypothesis-generating." |
"Our result is practice-changing." | "We have tempered the claim to state the finding informs the standard of care, and added the external-validity caveat on page 18." |
"We have addressed the data sharing concern." | "We have updated the Data Sharing statement to name the repository, access criteria, and availability window per ICMJE (page 22, lines 1 to 6)." |
The pattern that works at Lancet Oncology: concede where the reviewer is right, re-run the analysis when the statistical reviewer asks for it, point to the exact change, bound your interpretation to the data, and push back only on a request that is genuinely out of scope, with a reason and an alternative analysis.
The Lancet Oncology reviewer culture you are writing into
The two-stage editor-led screen
Lancet Oncology runs a two-stage, editor-led process. The first decision is made inside a professional clinical editorial group before any external reviewer is involved, which is why the desk-rejection rate is roughly 75%.
For the papers that clear that screen, the editors recruit about three clinical or subject reviewers plus one statistical reviewer. Clinical peer review and statistical review run in parallel, not in sequence. So when your reports arrive they already carry statistical scrutiny, and your rebuttal has to satisfy a referee whose only job was to ask whether the numbers support the claim.
We see the editors specifically look for one thing at re-review: whether the statistical-reviewer block answers each concern with a re-run number, not a defense. A clinical reply can be persuasive prose; the statistical reply has to be arithmetic.
What the Lancet statistical-review record tells you
The statistical reviewer is the defining feature of writing into the Lancet. The journal's own published audit of its statistical review process examined 191 papers and found only 54% acceptable or acceptable after revision, with 14% rejected and 32% needing substantial revision.
More telling for a rebuttal: that audit found major errors of inference in 48 papers, almost always alongside criticism of the analysis or design, with the recurring problems being thin descriptions of methods and results and conclusions that outran the data. That history names exactly what the statistical reviewer will probe in your revision: sample-size justification, multiple-testing adjustment, missing-data handling, subgroup and sensitivity-analysis logic, and whether the conclusion is justified by the design and the analysis.
The clock and the reporting standards
SciRev community data puts the first review round at roughly 0.7 months, with about 3.0 reports and around 2.0 review rounds, and authors rate the difficulty of the comments very high. That sets a tight planning clock: the Lancet group prizes speed, so the new analysis the statistical reviewer is likely to demand should be scoped before the decision letter arrives, not started after it.
Two policy facts then shape every clinical-trial rebuttal here:
- Lancet Oncology enforces reporting standards: CONSORT for randomized trials, PRISMA for systematic reviews, STROBE for observational studies, with the completed checklist submitted and checked against the manuscript.
- As an ICMJE member journal it requires a data sharing statement, which states whether deidentified participant data will be shared, what data, by what access mechanism, and for how long; trials enrolling participants on or after 1 January 2019 must also carry a data sharing plan in the trial registration.
A revision that fixes the text but leaves the checklist or the data sharing statement stale draws an immediate re-review comment.
Key Insight
At Lancet Oncology the statistical reviewer is a separate track running in parallel with the clinical referees. Answer that report with re-run numbers and an updated analysis plan, not with a paragraph defending the original. A contested statistical concern reopens whether your conclusion is justified at all.
What our Lancet Oncology rebuttal reviews surface
In our pre-submission review work with Lancet Oncology submissions, the rebuttals that stall in a second round or end in rejection share a small set of recurring, named, testable weaknesses. Each maps to a specific feature of the Lancet Oncology editorial culture, and each is checkable against your own draft response before you upload it.
Answering the statistical reviewer with prose instead of a re-analysis. The most common and most expensive pattern in our Lancet Oncology pre-submission reviews is a rebuttal that meets a statistical-reviewer concern about sample size, multiple comparisons, or missing data with a sentence explaining why the original analysis was adequate.
The statistical reviewer is not asking to be reassured; they are asking for the re-run number. When the report questions multiplicity, adding a paragraph does not move the decision; adding the adjusted p-value and the corrected statistical analysis does. Across our Lancet Oncology rebuttal reviews, this mismatch between what the reviewer requested and what the author delivered is the single strongest predictor of a rejection on revision.
Overstating clinical impact the data do not support. Lancet Oncology wants practice-changing work, which tempts authors to defend an overstated claim rather than temper it. In our pre-submission reviews of Lancet Oncology manuscripts, rebuttals that argue a single-setting trial is definitive, instead of conceding the external-validity limit and bounding the conclusion, read to the clinical referees as a failure of careful interpretation. The fix is almost always to soften the practice-changing language in the discussion and add the caveat, not to argue the point.
Leaving the reporting checklist or data sharing statement stale. A rebuttal that revises the methods text but resubmits the original CONSORT or PRISMA checklist, or leaves the data sharing statement without access criteria, forces an extra round. In our pre-submission review work with Lancet Oncology clinical-trial manuscripts, responses that omit the updated checklist item number or the ICMJE-compliant data sharing language consistently draw a re-review comment asking where the change is. Every Methods change needs a matching checklist update cited by item number.
Treating the statistical reviewer as one more clinical comment. Because clinical and statistical review run in parallel, a rebuttal that folds the statistical report into the general clinical replies, with no dedicated block, signals that the author did not take the methodology seriously. In our Lancet Oncology pre-submission reviews, the rebuttals we flag hardest bury a sample-size or effect-size concern three pages into a clinical reply. Give the statistical reviewer its own labeled section at the top, with the re-run numbers visible.
Run the re-analysis, bound the interpretation, refresh the checklist, and give the statistical reviewer its own block. That four-part discipline separates a Lancet Oncology rebuttal that clears one round from one that stalls or is rejected. Check your Lancet Oncology point-by-point response for these patterns before you submit.
Readiness check
Run the scan while The Lancet Oncology's requirements are in front of you.
See how this manuscript scores against The Lancet Oncology's requirements before you submit.
When to comply and when to push back
Situation | Recommended approach at Lancet Oncology |
|---|---|
Statistical reviewer requests a multiplicity adjustment | Comply. Re-run it, report the adjusted p-value, cite Methods page and line. |
Statistical reviewer questions sample size or power | Comply. Add the power calculation and the analysis plan; show the numbers. |
Statistical reviewer flags missing-data handling | Comply. Add the imputation or sensitivity analysis and report whether the conclusion holds. |
Clinical reviewer says the practice-changing claim is overstated | Comply. Temper the interpretation; add the external-validity caveat. |
Clinical reviewer asks for an experiment genuinely out of scope | Push back with a reason, add an alternative analysis, note the open question in the Discussion. |
Reviewer asks for global-health or LMIC framing | Comply. Add a short applicability paragraph; Lancet Oncology wants global relevance. |
Source: Manusights pre-submission reviews of Lancet Oncology-targeted resubmissions, 2025 cohort.
How much work a Lancet Oncology rebuttal actually takes
Authors consistently underestimate the statistical re-analysis effort and overestimate the writing effort. This breakdown is about workload, not the journal's decision clock; for the end-to-end schedule, see the Lancet Oncology review time guide and the Lancet Oncology submission guide.
Rebuttal task | Where the effort goes | What it costs you |
|---|---|---|
Reading and clustering the reports | Separating the statistical report from the clinical ones | A day of careful reading, not a skim |
Re-running the requested analysis | The actual bar for the statistical reviewer | The bulk of the work, often the rate-limiting step |
Refreshing the reporting checklist | Re-mapping every Methods change to a CONSORT or PRISMA item | Skipped most often, and it shows |
Tempering the interpretation | Bounding practice-changing claims to the data | One careful pass on the Discussion |
Writing the point-by-point replies | One reply plus a page and line reference per comment | Less than authors fear once the numbers exist |
Source: Manusights pre-submission reviews of Lancet Oncology resubmissions, 2025 cohort, last updated June 7, 2026.
Where the time actually goes
The rate-limiting step is the re-analysis the statistical reviewer asks for, not the writing. Authors who start the revision by drafting prose replies, then discover the re-run takes a week, are the ones who miss the Lancet group's short clock. Scope the new analysis first.
Honest friction: rejection on revision is real
A revision invitation at Lancet Oncology is not a soft acceptance. The journal desk-rejects roughly 75% of submissions and accepts only about 8% overall. The revised manuscript and your point-by-point response then go back to the editors, who usually return it to the same reviewers, including the statistical reviewer.
So the paper can still end in rejection after re-review if the re-analysis does not resolve the statistical concern or the interpretation still outruns the data. Most rejections at this stage trace to one cause: the author answered the statistical reviewer with prose instead of re-run numbers. The second most common is an overstated clinical claim the clinical referees would not let stand.
Think twice before you resubmit if any of these are true of your draft:
- The response uses generic "we have addressed this" language with no page or line numbers.
- The statistical reviewer asked for a re-analysis and you answered with a paragraph.
- A practice-changing claim survives in the Discussion that a single-setting trial cannot support.
- The reporting checklist or data sharing statement is unchanged from the first submission.
Fixing these before resubmission is what keeps a fast Lancet Oncology revision round from becoming a rejection.
Common mistakes a Lancet Oncology reviewer spots in seconds
Before you upload, scan your own rebuttal for the patterns that draw an immediate re-review comment. Each is a specific, checkable thing in your draft, not a vague quality dimension.
- A statistical reply with no new number. Any answer to the statistical reviewer that defends the original analysis without reporting a re-run result reads as evasion the moment the reviewer looks for the adjusted estimate.
- Prose where a re-analysis was requested. The statistical reviewer asked for a multiplicity adjustment or a missing-data sensitivity analysis and the reply only adds a sentence to the Methods.
This is the single most common cause of a rejection on revision.
- An overstated practice-changing claim left standing. A conclusion that a single trial redefines the standard of care, after a reviewer flagged the external-validity limit, signals a failure of careful interpretation.
- A stale reporting checklist. A revised Methods section paired with the original CONSORT or PRISMA checklist tells the editors the reporting standard was not re-checked.
How does this guide go beyond the Lancet Oncology author guidelines?
The official guidance tells you to submit a point-by-point response and to follow the reporting standards. It does not tell you that a separate statistical reviewer runs in parallel with the clinical referees, that the statistical report wants re-run numbers rather than reassurance, that the revision clock is short enough that the new analysis should be scoped before the decision letter, or that the practice-changing bar is bounded by careful interpretation.
Those four facts change how you write every reply. They come from our pre-submission reviews of Lancet Oncology rebuttals and the Lancet's own published statistical-review audit, and they are testable against your own draft today, not theoretical concerns.
Frequently asked questions
Yes. A Lancet Oncology research paper is usually assessed by about three clinical or subject reviewers plus one statistical reviewer, and clinical peer review and statistical review run in parallel rather than in sequence. So your reviewer reports arrive already carrying statistical scrutiny. The most expensive mistake in a Lancet Oncology rebuttal is answering a statistical-reviewer concern about sample size, multiplicity, or missing data with prose instead of a re-analysis.
Open with a short letter to the handling editor that summarizes the main concerns and the changes you made, then answer every comment in order under Reviewer 1, Reviewer 2, Reviewer 3, and the statistical reviewer. Copy each reviewer comment in full, keep reviewer text and your reply in two visually distinct fonts or colors, state the exact change, and give the page and line number in the revised manuscript plus the updated CONSORT or PRISMA checklist item where relevant.
The Lancet group moves fast and the revision window is usually shorter than at slower flagship journals. Community-reported data on SciRev puts the first review round at roughly 0.7 months and the typical paper at about 2 review rounds. Plan the new analysis the statistical reviewer is likely to request before the decision letter arrives, because a Lancet Oncology revision clock leaves little slack for a fresh statistical analysis plan.
Yes. A revision invitation is not an acceptance. The revised manuscript and your point-by-point response go back to the editors, who often send it to the same reviewers, including the statistical reviewer, for a second look. Lancet Oncology desk-rejects about three quarters of submissions and accepts only roughly 8% overall, so a revision that does not resolve the statistical or clinical-impact concern can still be rejected at re-review.
Sample-size justification, multiple-testing adjustment, missing-data handling, subgroup and sensitivity-analysis logic, and above all whether the conclusions are justified by the design and the analysis. A historical Lancet statistical-review audit of 191 papers found major errors of inference in 48 of them, almost always paired with criticism of the analysis or design. In a revision, the statistical reviewer wants the re-run numbers and the updated analysis plan, not a paragraph explaining why the original was adequate.
Sources
- Peer review, The Lancet (accessed June 2026)
- Journey of a Paper, The Lancet (accessed June 2026)
- The Lancet's statistical review process: areas for improvement by authors, PubMed, doi:10.1016/0140-6736(92)90409-V (accessed June 2026)
- Data sharing statements for clinical trials: a requirement of the ICMJE, PMC, doi:10.1016/S0140-6736(17)31282-5 (accessed June 2026)
- Ten simple rules for writing a response to reviewers, William Stafford Noble, PLOS Computational Biology, doi:10.1371/journal.pcbi.1005730 (accessed June 2026)
- How to respond to reviewers, Nature Computational Science, doi:10.1038/s43588-025-00931-5 (accessed June 2026)
- Reviews for Lancet Oncology, SciRev (accessed June 2026)
- Manusights pre-submission reviews of Lancet Oncology-targeted manuscripts (2025 cohort)
Final step
Submitting to The Lancet Oncology?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: The Lancet Oncology
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- How to Submit to Lancet Oncology: Complete Guide
- How to Avoid Desk Rejection at Lancet Oncology
- Lancet Oncology Review Time: What to Expect From Submission to Decision
- The Lancet Oncology 'Under Review': What Each Status Means
- Lancet Oncology Submission Process: What Happens After You Upload
- Rejected from The Lancet Oncology? The 7 Best Journals to Submit Next
Supporting reads
Conversion step
Submitting to The Lancet Oncology?
Anthropic Privacy Partner. Zero-retention manuscript processing.